Four more biotechs and a SPAC led by Bris­tol My­ers Squibb vet Matthew Ro­den have priced IPOs, clos­ing out an­oth­er busy week on Wall Street.

To­geth­er, Prax­is Pre­ci­sion Med­i­cines, Tar­sus Phar­ma­ceu­ti­cals, Ali­gos Ther­a­peu­tics, Kiromic Bio­Phar­ma and Turmer­ic Ac­qui­si­tion — MPM’s blank check com­pa­ny — have raised $528 mil­lion on their pub­lic de­buts.

Prax­is Pre­ci­sion Med­i­cines burst out of stealth mode with $100 mil­lion in May, quick­ly sweep­ing up an­oth­er $110 mil­lion in Ju­ly. And on Thurs­day, it raised $190 mil­lion — near­ly dou­ble its orig­i­nal goal — in an up­sized IPO. The Cam­bridge, MA-based biotech $PRAX of­fered 10 mil­lion shares at $19 apiece, up from its ini­tial of­fer of 7.4 mil­lion shares at a $17 to $18 range.

Be­tween $70 to $80 mil­lion are tagged for clin­i­cal de­vel­op­ment PRAX-114, the com­pa­ny’s lead CNS can­di­date. The mon­ey will fund a fu­ture Phase II/III tri­al in ma­jor de­pres­sive dis­or­der, and com­ple­tion of an on­go­ing Phase IIa. An­oth­er $30 to $40 mil­lion will go to­ward an on­go­ing Phase IIa study of PRAX-944 in es­sen­tial tremor. And $20 to $30 mil­lion should see a Phase I tri­al of PRAX-562 — Prax­is’ can­di­date for rare CNS dis­or­ders like se­vere pe­di­atric epilep­sy and adult cephal­gia — through com­ple­tion.

Since its launch, Prax­is has burned through more than $104 mil­lion, ac­cord­ing to the S-1/A. Black­stone holds 23.1% of the shares, fol­lowed by Even­tide with 9.4%, Vi­da Ven­tures with 7.3%, and No­vo Hold­ings with 6.6%.

“We ex­pect mul­ti­ple topline clin­i­cal tri­al read­outs from our three clin­i­cal-stage prod­uct can­di­dates pri­or to the end of 2021 and an­tic­i­pate the launch of a new clin­i­cal de­vel­op­ment pro­gram in 2021,” the S-1/A states.

Tar­sus Phar­ma­ceu­ti­cals al­so came in slight­ly above its ini­tial goal, rais­ing $88 mil­lion by pric­ing 5.5 mil­lion shares at $16 apiece. The Irvine, CA-based biotech $TARS filed for an $86 mil­lion IPO on Sept 25. It up­sized its of­fer by 575,000 shares, ac­cord­ing to an SEC fil­ing.

A ma­jor­i­ty of the pro­ceeds — about $65 mil­lion — will be poured in­to the com­pa­ny’s lead oph­thalmic can­di­date TP-03. The drug is cur­rent­ly in a Phase IIb/III tri­al for De­mod­ex ble­phar­i­tis, a con­di­tion char­ac­ter­ized by eye in­flam­ma­tion and caused by the in­fes­ta­tion of mites. Tar­sus ex­pects a Phase III launch in 2021. The re­main­ing funds may go to the biotech’s oth­er can­di­dates, TP-04 and TP-05, which it plans to en­ter in Phase I/II tri­als for rosacea and Ly­me dis­ease in 2021, re­spec­tive­ly.

Bobak Aza­mi­an

Since its found­ing in 2017, Tar­sus has spent a to­tal of $11.2 mil­lion. Vi­vo Cap­i­tal holds 15.77% of shares, while CEO Bobak Aza­mi­an has a 9.7% piece of the pie.

Ali­gos Ther­a­peu­tics $AL­GS filed for a $100 mil­lion IPO back in Sep­tem­ber to de­vel­op its chron­ic he­pati­tis B (CHB) and NASH ther­a­pies. Now the South San Fran­cis­co, CA-based biotech is rak­ing in $150 mil­lion through 10 mil­lion shares priced at $15 apiece, the mid­point of a $14 to $16 range.

About $40 to $43 mil­lion will go to­ward the com­pa­ny’s Phase I STOPS can­di­date ALG-010133, short for S-anti­gen trans­port-in­hibit­ing oligonu­cleotide poly­mer. An­oth­er $35 mil­lion to $38 mil­lion will fund an up­com­ing Phase I tri­al of its CAM (cap­sid as­sem­bly mod­u­la­tor) can­di­date ALG-000184. Twelve to $14 mil­lion will go to the NASH THR-b can­di­date ALG-055009. And Ali­gos ear­marked $12 to $15 mil­lion and $12 to $14 mil­lion for its CHB can­di­dates ALG-020572 and ALG-125097, re­spec­tive­ly.

The two-year-old biotech has spent $107 mil­lion, ac­cord­ing to its S-1/A. CEO Lawrence Blatt, for­mer head of in­fec­tious dis­ease at Janssen, holds 6.2% of shares. Roche Fi­nance, Ver­sant Ven­tures and Bak­er Broth­ers Ad­vi­sors each have 8.4% of the stock, fol­lowed by Vi­vo with 8.1%, No­vo with 6.6% and Welling­ton Man­age­ment with 5.2%.

Turmer­ic Ac­qui­si­tion, a blank check com­pa­ny formed by MPM Cap­i­tal, end­ed up down­siz­ing its of­fer from 10 mil­lion units to 8.5 mil­lion. The SPAC priced units at $10 each, rais­ing $85 mil­lion.

Matthew Ro­den

The com­pa­ny $TMP­MU is run by CEO Luke Evnin, who co-found­ed MPM Cap­i­tal in 1997, and chair­man Ro­den, who had a hand in Bris­tol My­ers Squibbs’ Cel­gene buy­out be­fore re­cent­ly join­ing MPM.

The duo — along­side the rest of the firm — now has two years to se­lect the pri­vate com­pa­ny to ride the shell of Turmer­ic to Nas­daq and in­her­it the in­vest­ment.

“We have not se­lect­ed any busi­ness com­bi­na­tion tar­get and we have not, nor has any­one on our be­half, ini­ti­at­ed any sub­stan­tive dis­cus­sions, di­rect­ly or in­di­rect­ly, with any busi­ness com­bi­na­tion tar­get,” the SPAC’s S-1/A states.

Kiromic Bio­Phar­ma $KRBP priced its shares at $12 apiece on Fri­day — the low end of its $12 to $14 range. The Hous­ton, TX-based biotech of­fered 1.3 mil­lion shares, rais­ing $15 mil­lion. The com­pa­ny is us­ing AI to de­vel­op can­cer ther­a­pies, and says the IPO funds will push its Alex­is iso­form mesothe­lin (for EOC) and PD-1 can­di­dates in­to the clin­ic.

By the end of last month, 56 biotechs had filed for IPOs this year — top­ping Brad Lon­car’s count of 47 last year. Both SQZ Biotech and Lux Health Tech Ac­qui­si­tion, a SPAC formed by Lux Cap­i­tal, filed to go pub­lic on Mon­day. SQZ pro­posed a $75 mil­lion raise to de­vel­op its cell ther­a­pies, while Lux is look­ing to nab $300 mil­lion. On Tues­day, Co­di­ak’s shares priced in at $15 apiece, net­ting $83 mil­lion.

Dupixent, the blockbuster anti-inflammatory drug from Sanofi and Regeneron, has cleared a high-stakes Phase III study in chronic obstructive pulmonary disease, the companies announced Thursday morning.

If they hold up in a second, identical trial, the data pave the way for Dupixent to become the first biologic to treat patients whose COPD remains uncontrolled despite being on maximal standard-of-care inhaled therapy — the patient population studied in the pivotal program. The companies had spotlighted this as a key readout as they look to expand the Dupixent franchise and explore its full potential.

Incyte touted an accelerated approval for its PD-1 retifanlimab in a rare skin cancer on Wednesday, roughly a year and a half after the drug suffered a rejection in squamous cell carcinoma of the anal canal (SCAC).

Retifanlimab, marketed as Zynyz, was approved for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a fast-growing skin cancer typically characterized by a single, painless nodule. It’s roughly 40 times rarer than melanoma, according to the nonprofit Skin Cancer Foundation — but incidence is growing, particularly among older adults, Incyte said in its announcement.